As the first iteration of the Collaborative Influenza Vaccine Innovation Centers (CIVICs) Program comes to an end, the Statistical, Data Management, and Coordination Center (SDMCC) collaborated with CIVICs investigators to reflect on the accomplishments and impact of the CIVICs Program. The main aim of the CIVICs Program was to accelerate the development of more durable, broadly protective, and longer-lasting influenza vaccines by linking pre-clinical research, manufacturing, clinical trials, and human challenge studies into one unified program. CIVICs leaders from the National Institute of Allergy and Infectious Diseases (NIAID) further describe the origin and goals of CIVICs in a commentary in Vaccine. The SDMCC is highlighting the vaccine candidates and human challenge studies developed and led by CIVICs to share how the Program’s efforts improved influenza vaccine science and disease outcomes.